IMAP statement on Norplant subdermal contraceptive implant system.
D000554:Ambulatory Care Facilities; D001695:Biology; D003267:Contraception; D003268:Contraception Behavior; D003270:Contraceptive Agents; D003271:Contraceptive Agents, Female; D003376:Counseling; D005193:Family Planning Services; D006285:Health Planning; D016912:Levonorgestrel; D008660:Metabolism; D010342:Patient Acceptance of Health Care; D010827:Physiology; D013812:Therapeutics
D003270:Contraceptive Agents; D003271:Contraceptive Agents, Female; D016912:Levonorgestrel
Biology; Clinic Activities; Contraception; Contraception Continuation; Contraceptive Agents, Female--beneficial effects; Contraceptive Agents, Female--contraindications; Contraceptive Agents, Female--side effects; Contraceptive Agents, Progestin--beneficial effects; Contraceptive Agents, Progestin--contraindications; Contraceptive Agents, Progestin--side effects; Contraceptive Agents--beneficial effects; Contraceptive Agents--contraindications; Contraceptive Agents--side effects; Contraceptive Effectiveness; Contraceptive Implants; Contraceptive Methods; Contraceptive Mode Of Action; Contraceptive Usage; Counseling; Family Planning; Insertion; Levonorgestrel--beneficial effects; Levonorgestrel--contraindications; Levonorgestrel--side effects; Metabolic Effects; Method Acceptability; Physiology; Program Activities; Programs; Reversibility; Treatment